Silence Therapeutics to Present at Jefferies Global Healthcare Conference

Rhea-AI Summary

Silence Therapeutics (Nasdaq: SLN) announced its participation in the Jefferies Global Healthcare Conference on June 6th at 2:30 p.m. ET. The company, known for its innovative biotechnology solutions aimed at silencing diseases through precision-engineered medicines, will provide a presentation accessible via live webcast on the company's investor section. An archived replay will also be available after the event.

Positive

• Participation in a high-profile event like the Jefferies Global Healthcare Conference enhances the company's visibility in the biotech sector.
• The live webcast and archived replay increase accessibility for investors and stakeholders to stay informed about the company's progress.

Negative

• The press release lacks details on any significant business developments or financial updates, which may leave investors seeking more substantive information.

LONDON--(BUSINESS WIRE)-- Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the “Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced the Company will present at the Jefferies Global Healthcare Conference on Thursday, June 6^th at 2:30 p.m. ET.

The live webcast can be accessed via the Investors section of the Silence website at www.silence-therapeutics.com. An archived replay of the webcast will be available following the conference.

About Silence Therapeutics
Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet need. Silence's proprietary mRNAi GOLD™ platform can be used to create siRNAs (short interfering RNAs) that precisely target and silence disease-associated genes in the liver, which represents a substantial opportunity. Silence's wholly owned product candidates include zerlasiran designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of lipoprotein(a) and divesiran designed to address rare hematological diseases, including polycythemia vera. Silence also maintains ongoing research and development collaborations with AstraZeneca and Hansoh Pharma, among others. For more information, please visit https://www.silence-therapeutics.com/.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240530788603/en/

Inquiries:

Silence Therapeutics plc

Gem Hopkins, VP, Head of IR and Corporate Communications

ir@silence-therapeutics.com

Tel: +1 (646) 637-3208

Source: Silence Therapeutics plc

FAQ

When will Silence Therapeutics present at the Jefferies Global Healthcare Conference?

Silence Therapeutics will present on June 6th at 2:30 p.m. ET.

Where can I access the live webcast of Silence Therapeutics' presentation?

The live webcast can be accessed via the Investors section of the Silence Therapeutics website.

Will there be an archived replay of Silence Therapeutics' Jefferies Conference presentation?

Yes, an archived replay will be available following the conference.

What is the stock symbol for Silence Therapeutics?

The stock symbol for Silence Therapeutics is SLN.